Eli Lilly and contract manufacturer Resilience are investing $750 million to expand pharmaceutical production in the Cincinnati region, adding Lilly's KwikPen injectable device to Resilience's operations. The expansion will create at least 400 high-skilled jobs, bringing Resilience's Ohio headcount above 1,400, with site preparation underway and full operations expected in early 2027. The KwikPen delivers Lilly's diabetes and obesity medicines, though neither company specified which drugs will be filled at the site. The partnership, which began in 2023, has already produced more than 150 million doses for U.S. patients in vial and pre-filled syringe formats. Lilly's U.S. capital commitments since 2020 now exceed $55 billion, with several announced sites due to break ground this year.
Eli Lilly and CompanyExpansion of manufacturing capacity for KwikPen injectable device, supporting production of diabetes and obesity drugs.
Resilience receives $750M investment and contract to manufacture Lilly's KwikPen, expanding its operations and creating jobs.